Bris­tol My­ers rolls out 3-year mesothe­lioma da­ta for Op­di­vo/Yer­voy in first look at ES­MO slate

The Op­di­vo/Yer­voy im­munother­a­py com­bo from Bris­tol My­ers Squibb has earned some skep­ti­cism over the years from re­searchers ques­tion­ing the ef­fi­ca­cy of CT­LA-4 in fight­ing tu­mors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER